Banca de QUALIFICAÇÃO: ANANÍLIA MEDEIROS GOMES DA SILVA

Uma banca de QUALIFICAÇÃO de MESTRADO foi cadastrada pelo programa.
DISCENTE: ANANÍLIA MEDEIROS GOMES DA SILVA
DATA: 28/07/2015
HORA: 14:00
LOCAL: SALA DE AULA II DO PPGCF
TÍTULO:

CIRCULATING miRNAS AS BIOMARKERS FOR NEW-ONSET ATRIAL FIBRILLATION


PALAVRAS-CHAVES:

Atrial Fibrillation; Biomarkers; miRNA; new-onset AF


PÁGINAS: 20
GRANDE ÁREA: Ciências da Saúde
ÁREA: Farmácia
RESUMO:

Introduction Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. The methods for diagnosing AF are limited to electrocardiogram (ECG) analysis. In this context, studies have demonstrated the regulatory activity of microRNAs (miRNAs) in arrhythmogenesis, targeting genes involved in the development of AF. However, the role of miRNAs as biomarkers for diagnosis of AF is not well evaluated yet. Methods Six miRNAs (miR-21, miR-133a, miR-133b, miR-150, miR-328 and miR-499) were selected as targets in the study. They were isolated from plasma of individuals aged 20-85 years with AF (n = 17), new-onset AF (n = 5) and without AF (n = 15). The results were analyzed and validated by Real-Time PCR (RT-PCR) using miScript SYBR Green PCR. Results The miR-21, miR-133b, miR-328 and miR-499 were differently expressed among the three groups (p <0.05), and also between patients with atrial fibrillation (AF vs. new-onset AF, p <0.05). miR-133b and miR-499 expression were also different for individuals with new-onset AF vs. controls. Increased expression of miR-21 (0.6-fold), miR-133b (1.4-fold), miR-328 (2.0-fold) and miR-499 (2.3-fold) were observed in individuals with new-onset AF and AF compared with control. miR-133a and miR-150 expression did not differ among groups. Conclusion Before our findings, we suggest that miR-21, miR-133b, miR-328 and miR-499 may be potential biomarkers for AF as well as for new-onset AF, for the diagnosis and monitoring of disease. These findings may contribute to understanding the process that triggers the AF and its acute event, encouraging the development of new studies to evaluate the application of these molecules as future clinical markers for this disease.


MEMBROS DA BANCA:
Externo ao Programa - 1714243 - DANIELLA REGINA ARANTES MARTINS SALHA
Presidente - 1544647 - MATHEUS DE FREITAS FERNANDES PEDROSA
Externo ao Programa - 1199127 - SILVIA REGINA BATISTUZZO DE MEDEIROS
Notícia cadastrada em: 15/07/2015 15:56
SIGAA | Superintendência de Tecnologia da Informação - (84) 3342 2210 | Copyright © 2006-2024 - UFRN - sigaa14-producao.info.ufrn.br.sigaa14-producao